Literature DB >> 35091679

TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer.

Yan Ma1, Haibo Zhang2, Cheng Chen3, Lixin Liu4, Ting Ding5, Ying Wang2, Dachang Ma3, Xiaoling Ling6, Xiaohua Chen1, Jianping Li7, Guoqing Ru8, Lei Zhang9, Jianming Tang10.   

Abstract

Radioresistance is common in the treatment of triple-negative breast cancer (TNBC), but the molecular mechanisms involved remain unclear. Herein, we reveal that tripartite motif-containing protein 32 (TRIM32) is upregulated in TNBC and is negatively associated with survival of TNBC patients. Radiotherapy resulted in enhanced expression of TRIM32, whereas TRIM32 depletion reduced TNBC radioresistance in vitro and in vivo. Mechanistically, radiotherapy promoted the association between TRIM32 and nuclear STAT3, which suppressed TC45-induced dephosphorylation of STAT3, resulting in increased STAT3 transcriptional activation and TNBC radioresistance. Finally, we demonstrated that TRIM32 and STAT3 phosphorylation are co-expressed in TNBC tissues. Moreover, high expression of TRIM32 and STAT3 phosphorylation is positively linked to poor prognosis of TNBC patients. Our study demonstrates that TRIM32 is a novel target for predicting radioresistance in TNBC patients.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35091679     DOI: 10.1038/s41388-022-02204-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  1 in total

1.  TRIM32 Promotes the Growth of Gastric Cancer Cells through Enhancing AKT Activity and Glucose Transportation.

Authors:  Jianjun Wang; Yuejun Fang; Tao Liu
Journal:  Biomed Res Int       Date:  2020-01-21       Impact factor: 3.411

  1 in total
  1 in total

1.  Up-Regulation of TRIM32 Associated With the Poor Prognosis of Acute Myeloid Leukemia by Integrated Bioinformatics Analysis With External Validation.

Authors:  Xiaoyan Xu; Jiaqian Qi; Jingyi Yang; Tingting Pan; Haohao Han; Meng Yang; Yue Han
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.